Biolargo, INC.: insider trades · United States · SEC (Form 4)

About Biolargo, INC.

BioLargo, Inc. (ticker: BLGO) is a United States-based company with shares quoted on the OTCQX market; it is not listed on NYSE or NASDAQ, but it is often analyzed like a small-cap cleantech platform with a heavy emphasis on intellectual property and commercialization risk. The company is headquartered in Westminster, California, is incorporated in Delaware, and operates from several locations, including Westminster, Oak Ridge, Tennessee, Alberta in Canada, and Tampa, Florida. Its footprint reflects a business that combines environmental technologies, industrial products, and early-stage life sciences assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm)) BioLargo has built its strategy around developing, protecting, and commercializing proprietary technologies rather than competing as a broad industrial conglomerate. According to its SEC filings, the company reports six operating business segments plus corporate functions. The most visible businesses are ONM Environmental, which sells odor and volatile organic compound control products and related services; BioLargo Equipment Solutions & Technologies, which houses water-treatment solutions; Clyra Medical, its medical products unit; and additional technology efforts tied to energy and environmental applications. This structure gives BioLargo exposure to multiple end markets, but it also means investors should view the company as a portfolio of projects rather than a single mature operating franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm)) From a competitive standpoint, BioLargo positions itself as a niche innovator in environmental remediation and odor control. Its flagship commercial product, CupriDyne Clean, is used for industrial odor control, and the company describes it as the market’s number-one performing odor-control product. In water treatment, BioLargo’s Aqueous Electrostatic Concentrator (AEC) is designed to remove PFAS from water at lower operating cost and with less waste than common alternatives such as carbon filtration, ion exchange, and reverse osmosis. The company also references adjacent technologies such as AROS for water reuse and recycling, and AOS for micropollutant treatment and energy-efficient disinfection. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm)) Geographically, BioLargo remains primarily North American. Its California headquarters also houses manufacturing, while research and engineering capabilities are spread across Canada and Tennessee. On the healthcare side, Clyra Medical is based in Tampa, Florida. That geographic mix supports a cross-border R&D model, but it also underscores the company’s relatively modest scale and dependence on execution across several technically demanding programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/880242/000143774925010172/blgo20241231_10k.htm)) Recent developments have been especially important for the equity story. In 2025, BioLargo reported internal and third-party testing showing more than 99% removal of ultrashort-chain PFAS, including TFA, using its AEC technology. It also initiated alpha testing of a portable PFAS water test kit through Verralize. In February 2026, Clyra Medical received its first commercial stocking order for ViaCLYR, described as an FDA-cleared wound irrigation solution, marking an early revenue-generating milestone. In September 2025, BioLargo said it revoked a technology license granted to Pooph after contractual breaches and unpaid amounts, highlighting both the upside of technology licensing and the legal/collection risk that can accompany it. ([biolargo.com](https://www.biolargo.com/post/biolargo-demonstrates-over-99-removal-of-ultrashort-chain-pfas-including-tfa-using-aqueous-electros)) Overall, BioLargo should be viewed as a U.S. cleantech and life-sciences micro-cap with meaningful optionality, but also with high execution risk, ongoing commercialization needs, and a business model that still depends on converting technical validation into scalable revenue.